Your browser doesn't support javascript.
loading
Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.
Ringe, Rajesh P; Yasmeen, Anila; Ozorowski, Gabriel; Go, Eden P; Pritchard, Laura K; Guttman, Miklos; Ketas, Thomas A; Cottrell, Christopher A; Wilson, Ian A; Sanders, Rogier W; Cupo, Albert; Crispin, Max; Lee, Kelly K; Desaire, Heather; Ward, Andrew B; Klasse, P J; Moore, John P.
Afiliación
  • Ringe RP; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
  • Yasmeen A; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
  • Ozorowski G; Department of Integrative Structural and Computational Biology, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, USA.
  • Go EP; Department of Chemistry, University of Kansas, Lawrence, Kansas, USA.
  • Pritchard LK; Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, United Kingdom.
  • Guttman M; Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USA.
  • Ketas TA; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
  • Cottrell CA; Department of Integrative Structural and Computational Biology, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, USA.
  • Wilson IA; Department of Integrative Structural and Computational Biology, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, USA The Skaggs Institute for Chemical Biology, The Scripps Research Institute,
  • Sanders RW; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Cupo A; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
  • Crispin M; Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, United Kingdom.
  • Lee KK; Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USA.
  • Desaire H; Department of Chemistry, University of Kansas, Lawrence, Kansas, USA.
  • Ward AB; Department of Integrative Structural and Computational Biology, IAVI Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, USA.
  • Klasse PJ; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
  • Moore JP; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA jpm2003@med.cornell.edu.
J Virol ; 89(23): 12189-210, 2015 Dec.
Article en En | MEDLINE | ID: mdl-26311893
UNLABELLED: We have investigated factors that influence the production of native-like soluble, recombinant trimers based on the env genes of two isolates of human immunodeficiency virus type 1 (HIV-1), specifically 92UG037.8 (clade A) and CZA97.012 (clade C). When the recombinant trimers based on the env genes of isolates 92UG037.8 and CZA97.012 were made according to the SOSIP.664 design and purified by affinity chromatography using broadly neutralizing antibodies (bNAbs) against quaternary epitopes (PGT145 and PGT151, respectively), the resulting trimers are highly stable and they are fully native-like when visualized by negative-stain electron microscopy. They also have a native-like (i.e., abundant) oligomannose glycan composition and display multiple bNAb epitopes while occluding those for nonneutralizing antibodies. In contrast, uncleaved, histidine-tagged Foldon (Fd) domain-containing gp140 proteins (gp140UNC-Fd-His), based on the same env genes, very rarely form native-like trimers, a finding that is consistent with their antigenic and biophysical properties and glycan composition. The addition of a 20-residue flexible linker (FL20) between the gp120 and gp41 ectodomain (gp41ECTO) subunits to make the uncleaved 92UG037.8 gp140-FL20 construct is not sufficient to create a native-like trimer, but a small percentage of native-like trimers were produced when an I559P substitution in gp41ECTO was also present. The further addition of a disulfide bond (SOS) to link the gp120 and gp41 subunits in the uncleaved gp140-FL20-SOSIP protein increases native-like trimer formation to ∼20 to 30%. Analysis of the disulfide bond content shows that misfolded gp120 subunits are abundant in uncleaved CZA97.012 gp140UNC-Fd-His proteins but very rare in native-like trimer populations. The design and stabilization method and the purification strategy are, therefore, all important influences on the quality of trimeric Env proteins and hence their suitability as vaccine components. IMPORTANCE: Soluble, recombinant multimeric proteins based on the HIV-1 env gene are current candidate immunogens for vaccine trials in humans. These proteins are generally designed to mimic the native trimeric envelope glycoprotein (Env) that is the target of virus-neutralizing antibodies on the surfaces of virions. The underlying hypothesis is that an Env-mimetic protein may be able to induce antibodies that can neutralize the virus broadly and potently enough for a vaccine to be protective. Multiple different designs for Env-mimetic trimers have been put forth. Here, we used the CZA97.012 and 92UG037.8 env genes to compare some of these designs and determine which ones best mimic virus-associated Env trimers. We conclude that the most widely used versions of CZA97.012 and 92UG037.8 oligomeric Env proteins do not resemble the trimeric Env glycoprotein on HIV-1 viruses, which has implications for the design and interpretation of ongoing or proposed clinical trials of these proteins.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Recombinantes / Ingeniería de Proteínas / VIH-1 / Productos del Gen env del Virus de la Inmunodeficiencia Humana / Multimerización de Proteína Idioma: En Revista: J Virol Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Recombinantes / Ingeniería de Proteínas / VIH-1 / Productos del Gen env del Virus de la Inmunodeficiencia Humana / Multimerización de Proteína Idioma: En Revista: J Virol Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos